Highlights Kringle Pharma, Inc.

Equities

4884

JP3270790003

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-17 EDT			5-day change	1st Jan Change
650 ^JPY	+13.24%		+19.27%	-13.56%

02-09	Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	CI
2023	Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	02-08	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	11-28	CI
Kringle Pharma, Inc. Completes Its Pre-Ind (Investigation New Drug) Meeting with the U.S. Food and Drug Administration Regarding the Development Plan of Kp-100It, A Lyophilized Formulation of Recombinant Human Hgf, for the Potential Treatment of Acute Spinal Cord Injury	11-17	CI
Kringle Pharma, Inc. Announces Publication of Preclinical Results from Joint Research with Keio University on Severe Spinal Cord Injury	23-10-30	CI
Kringle Pharma, Inc. Announces Last Patient Out in Phase 3 Study of KP-100IT for the Treatment of Acute Spinal Cord Injury	23-10-02	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	23-08-30	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	23-05-29	CI
Kringle Pharma, Inc. Announces Last Patient Enrolled in Phase Iii Study for the Treatment of Acute Spinal Cord Injury	23-04-13	CI
Kringle Pharma, Inc. Announces Patent Application Claims Priority for the Treatment of Chronic Spinal Cord Injury	23-03-12	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	23-02-27	CI
Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar	23-01-16	CI
Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury	23-01-12	CI
Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023	22-12-01	CI
Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar	22-11-23	CI
Kringle Pharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-11-13	CI
Kringle Pharma, Inc. Submits Clinical Trial Application	22-10-23	CI
Kringle Pharma, Inc. Announces Jointly File A Patent Application with Keio University	22-09-08	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022	22-08-26	CI
Kringle Pharma, Inc. Updates on the Investigator-initiated Phase 2 Study in Patients with ALS	22-08-12	CI
Kringle Pharma, Inc. Announces Signing of Collaborative Research Agreement with Kyoto University	22-06-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kringle Pharma, Inc.

Equities

4884

JP3270790003

Highlights

Filters